Durvalumab vs Exenatide

Durvalumab vs Exenatide: Overview

This comparison examines the pharmacological differences between Durvalumab and Exenatide.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Exenatide: Synthetic exendin-4 GLP-1 receptor agonist enhancing glucose-dependent insulin secretion.

Pharmacokinetics

Half-life: Durvalumab — 17 days; Exenatide — 2.4 hours.

Chemical Properties

Type: Durvalumab — Antibody; Exenatide — Protein.